19789873

Source:http://linkedlifedata.com/resource/pubmed/id/19789873

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0003392, umls-concept:C0027270, umls-concept:C0034037, umls-concept:C0036043, umls-concept:C0814812, umls-concept:C0879285, umls-concept:C0920321, umls-concept:C1274040, umls-concept:C1511726, umls-concept:C1704324
pubmed:issue	6
pubmed:dateCreated	2010-3-16
pubmed:abstractText	Depletion of cellular nicotinamide adenine dinucleotide (NAD) by inhibition of its synthesis is a new pharmacological principle for cancer treatment currently in early phases of clinical development. We present new and previously published data on the safety and efficacy of these drugs based on early clinical trials.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7806519
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Acrylamides, http://linkedlifedata.com/resource/pubmed/chemical/Cyanides, http://linkedlifedata.com/resource/pubmed/chemical/Guanidines, http://linkedlifedata.com/resource/pubmed/chemical/N-(4-(1-benzoylpiperidin-4-yl)butyl)..., http://linkedlifedata.com/resource/pubmed/chemical/N-(6-chlorophenoxyhexyl)-N''-cyano-N..., http://linkedlifedata.com/resource/pubmed/chemical/NAD, http://linkedlifedata.com/resource/pubmed/chemical/Nicotinamide..., http://linkedlifedata.com/resource/pubmed/chemical/Piperidines
pubmed:status	MEDLINE
pubmed:month	May
pubmed:issn	1432-0843
pubmed:author	pubmed-author:BerglundAkeA, pubmed-author:LarssonRolfR, pubmed-author:NygrenPeterP, pubmed-author:von HeidemanAnneA
pubmed:issnType	Electronic
pubmed:volume	65
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1165-72
pubmed:meshHeading	pubmed-meshheading:19789873-Acrylamides, pubmed-meshheading:19789873-Aged, pubmed-meshheading:19789873-Clinical Trials, Phase I as Topic, pubmed-meshheading:19789873-Cyanides, pubmed-meshheading:19789873-Dose-Response Relationship, Drug, pubmed-meshheading:19789873-Drug Administration Schedule, pubmed-meshheading:19789873-Fatigue, pubmed-meshheading:19789873-Female, pubmed-meshheading:19789873-Guanidines, pubmed-meshheading:19789873-Humans, pubmed-meshheading:19789873-Male, pubmed-meshheading:19789873-Meta-Analysis as Topic, pubmed-meshheading:19789873-Middle Aged, pubmed-meshheading:19789873-NAD, pubmed-meshheading:19789873-Nausea, pubmed-meshheading:19789873-Neoplasms, pubmed-meshheading:19789873-Nicotinamide Phosphoribosyltransferase, pubmed-meshheading:19789873-Piperidines, pubmed-meshheading:19789873-Thrombocytopenia, pubmed-meshheading:19789873-Treatment Outcome, pubmed-meshheading:19789873-Vomiting
pubmed:year	2010
pubmed:articleTitle	Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data.
pubmed:affiliation	Department of Oncology, Radiology and Clinical Immunology, Section of Oncology, University Hospital, Uppsala University, 751 85, Uppsala, Sweden.
pubmed:publicationType	Journal Article, Clinical Trial, Phase I